Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis
暂无分享,去创建一个
Christian Hampp | Casie E. Horgan | Catherine A. Panozzo | Judith C. Maro | S. Dutcher | J. Maro | Richard S. Swain | Casie Horgan | Andrew B Petrone | C. Hampp | Elizabeth C. Dee | Yandong Qiang | Rong Chen Tilney | C. Panozzo | Elizabeth Dee | Yandong Qiang | Sarah K. Dutcher | Andrew Petrone | Rong Chen Tilney | E. Dee
[1] E. Schroeder,et al. Validation of an algorithm for identifying type 1 diabetes in adults based on electronic health record data , 2018, Pharmacoepidemiology and drug safety.
[2] B. Zinman,et al. Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials , 2018, Diabetes Care.
[3] K. Brodovicz,et al. Incidence and prevalence of diabetic ketoacidosis (DKA) among adults with type 1 diabetes mellitus (T1D): a systematic literature review , 2017, BMJ Open.
[4] I. Harman-boehm,et al. Diabetic ketoacidosis: clinical characteristics, precipitating factors and outcomes of care. , 2012, The Israel Medical Association journal : IMAJ.
[5] L. Geiss,et al. Trends in Diabetic Ketoacidosis Hospitalizations and In-Hospital Mortality — United States, 2000–2014 , 2018, MMWR. Morbidity and mortality weekly report.
[6] K. Sullivan,et al. OpenEpi: Open Source Epidemiologic Statistics for Public Health. Version 2.3.1. , 2013 .
[7] R. Platt,et al. Automated Detection and Classification of Type 1 Versus Type 2 Diabetes Using Electronic Health Record Data , 2013, Diabetes Care.
[8] Jingli Lu,et al. Effects of sodium‐glucose cotransporter (SGLT) inhibitors in addition to insulin therapy on glucose control and safety outcomes in adults with type 1 diabetes: A meta‐analysis of randomized controlled trials , 2019, Diabetes/metabolism research and reviews.
[9] T. Oron,et al. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium–Glucose Cotransporter (SGLT) Inhibitors , 2019, Diabetes Care.
[10] Martijn J Schuemie,et al. Incidence of diabetic ketoacidosis among patients with type 2 diabetes mellitus treated with SGLT2 inhibitors and other antihyperglycemic agents. , 2017, Diabetes research and clinical practice.
[11] P. Lapuerta,et al. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.
[12] B. Zinman,et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2015, The New England journal of medicine.
[13] E. Mayer-Davis,et al. Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study , 2018, Diabetes Care.
[14] P. Ueda,et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study , 2018, British Medical Journal.
[15] C. Koebnick,et al. Validity of ICD-10-CM codes for determination of diabetes type for persons with youth-onset type 1 and type 2 diabetes , 2019, BMJ Open Diabetes Research & Care.
[16] M. Phillip,et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study , 2018, Diabetes Care.
[17] R. Beck,et al. Severe hypoglycemia and diabetic ketoacidosis in adults with type 1 diabetes: results from the T1D Exchange clinic registry. , 2013, The Journal of clinical endocrinology and metabolism.
[18] K. Mahaffey,et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes , 2017, The New England journal of medicine.
[19] D. O'Neal,et al. SGLT2 Inhibitors Increase the Risk of Diabetic Ketoacidosis Developing in the Community and During Hospital Admission. , 2019, The Journal of clinical endocrinology and metabolism.
[20] P. Lapuerta,et al. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study , 2018, Diabetes Care.
[21] Richard Platt,et al. The FDA Sentinel Initiative - An Evolving National Resource. , 2018, The New England journal of medicine.
[22] K. Lee,et al. Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: A nationwide population‐based cohort study , 2018, Diabetes, obesity & metabolism.
[23] S. Saydah,et al. Prevalence of Diagnosed Diabetes in Adults by Diabetes Type — United States, 2016 , 2018, MMWR. Morbidity and mortality weekly report.
[24] Richard Platt,et al. The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot program , 2012, Pharmacoepidemiology and drug safety.
[25] B. Anderson,et al. Insulin Omission in Women With IDDM , 1994, Diabetes Care.
[26] W. Bobo,et al. Positive predictive value of automated database records for diabetic ketoacidosis (DKA) in children and youth exposed to antipsychotic drugs or control medications: a tennessee medicaid study , 2011, BMC medical research methodology.
[27] Zhiguang Zhou,et al. Incretin-based therapies for patients with type 1 diabetes: a meta-analysis , 2019, Endocrine connections.
[28] D. Boyle,et al. The diabetes audit and research in Tayside Scotland (darts) study: electronic record linkage to create a diabetes register , 1997, BMJ.
[29] C. Mathieu,et al. Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial , 2018, Diabetes Care.
[30] Barbara Evans,et al. A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.
[31] H. Rodbard,et al. The Effect of Canagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, on Glycemic End Points Assessed by Continuous Glucose Monitoring and Patient-Reported Outcomes Among People With Type 1 Diabetes , 2016, Diabetes Care.
[32] R. Henry,et al. Efficacy and Safety of Canagliflozin, a Sodium–Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes , 2015, Diabetes Care.
[33] A. Avogaro,et al. Sodium‐glucose co‐transporter‐2 inhibitors and diabetic ketoacidosis: An updated review of the literature , 2018, Diabetes, obesity & metabolism.
[34] P. Lapuerta,et al. HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study , 2018, Diabetes Care.
[35] S. Schneeweiss,et al. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. , 2017, The New England journal of medicine.